Enanta Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Enanta Pharmaceuticals has a total shareholder equity of $191.9M and total debt of $189.5M, which brings its debt-to-equity ratio to 98.8%. Its total assets and total liabilities are $428.5M and $236.6M respectively.
Key information
98.8%
Debt to equity ratio
US$189.55m
Debt
Interest coverage ratio | n/a |
Cash | US$337.15m |
Equity | US$191.88m |
Total liabilities | US$236.62m |
Total assets | US$428.50m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9EP's short term assets ($390.3M) exceed its short term liabilities ($62.4M).
Long Term Liabilities: 9EP's short term assets ($390.3M) exceed its long term liabilities ($174.2M).
Debt to Equity History and Analysis
Debt Level: 9EP has more cash than its total debt.
Reducing Debt: 9EP's debt to equity ratio has increased from 0.4% to 98.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9EP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 9EP has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 54.5% each year.